Ipsen: UBS reiterates buy recommendation

(CercleFinance.com) - UBS reiterates its Buy recommendation on the stock, with a target price of E145, representing 41% upside potential.


"We acknowledge the likely increased competition for elafibranor given GILD/CBAY acquisition, but we note moderate cons expectation for elafibranor peak sales".

The investigational once-daily oral drug could become the first new second-line treatment for primary biliary cholangitis, a rare cholestatic liver disease, in almost a decade, the group said.

The European Medicines Agency has approved elafibranor's marketing authorization application. The US. FDA has accepted elafibranor's marketing authorization application.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.